- Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024
- Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
- Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development
- Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
- Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award
- Adlai Nortye Ltd. Announces Closing of Initial Public Offering
- Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
More ▼
Key statistics
52-week range
Open | 4.60 |
---|---|
High | 4.78 |
Low | 3.91 |
Bid | 3.94 |
Offer | 4.12 |
Previous close | 4.29 |
Average volume | 47.26k |
---|---|
Shares outstanding | 12.30m |
Free float | 0.00 |
P/E (TTM) | -- |
Market cap | 267.90m USD |
EPS (TTM) | -7.26 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 16:42 BST.
More ▼